Worth reading
37Immaterial
Scored from 3 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
3
Cases (dystrophic epidermolysis bullosa trial, out of 4)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentation2 items taken from the company’s own explanation
What the company explained in this material
New initiatives
Determination of future development policy and development support for dystrophic epidermolysis bullosaKey KPIsA metric the company considers important as a management benchmark.
- Closure of refractory ulcers3 of 4 cases
- 90-day mRS for acute ischemic strokeNo statistically significant improvement over the placebo group
- Incidence of adverse eventsSimilar in the Redasemtide and placebo groups
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Key KPIs | Indicator name Closure of refractory ulcers / Value 3 of 4 cases / Year on year against the same period last year Not disclosed, Indicator name 90-day mRS for acute ischemic stroke / Value No statistically significant improvement over the placebo group / Year on year against the same period last year Not disclosed, Indicator name Incidence of adverse events / Value Similar in the Redasemtide and placebo groups / Year on year against the same period last year Not disclosed |
| New initiatives | Determination of future development policy and development support for dystrophic epidermolysis bullosa |
Items this document does not state (28)
Fiscal Period CoveredNet SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the dystrophic epidermolysis bullosa trial, closure of refractory ulcers, the primary endpoint, was achieved in 3 of 4 cases. In the acute ischemic stroke trial, the Redasemtide group did not show a statistically significant improvement over the placebo group in the modified Rankin Scale (mRS) 90 days after onset. No new safety concerns were identified in either trial, and good tolerability was confirmed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.